Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genprex, Inc. - Common Stock (NQ:GNPX)

0.2750 +0.0205 (+8.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 32.66% to $7.92 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of... 
Via Benzinga
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
From Genprex, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) stock rose 21.47% to $5.26 during Friday's pre-market session. The company's market cap stands at $68.5 million.... 
Via Benzinga
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
From Genprex, Inc.
Via Business Wire
Genprex to Participate in Upcoming May Investor Conferences
From Genprex, Inc.
Via Business Wire
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
From Genprex, Inc.
Via Business Wire
Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference
- One Day Conference May 11, 2021 - 25 Minute Presenting Time Slots From 8:30am to 1:25pm EST - Presentation Times and Links Distributed for All Presenting Companies - Investors Will Be Provided Time... 
From Diamond Equity Research LLC
Via AccessWire
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Genprex to Participate in CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
From Genprex, Inc.
Via Business Wire
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
From Genprex, Inc.
Via Business Wire
44 Biggest Movers From Yesterday
Gainers Chemomab Therapeutics Ltd. (NASDAQ: CMMB) shares jumped 111.5% to close at $55.00 on Thursday. ORBCOMM Inc. (NASDAQ: ORBC) gained 52.1% to close at $11.51 on Thursday. GI... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.